A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer.
about
Pazopanib, a novel multi-kinase inhibitor, shows potent antitumor activity in colon cancer through PUMA-mediated apoptosis.UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice.Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review.Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.
P2860
A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
A phase I open-label study of ...... metastatic colorectal cancer.
@en
A phase I open-label study of ...... metastatic colorectal cancer.
@nl
type
label
A phase I open-label study of ...... metastatic colorectal cancer.
@en
A phase I open-label study of ...... metastatic colorectal cancer.
@nl
prefLabel
A phase I open-label study of ...... metastatic colorectal cancer.
@en
A phase I open-label study of ...... metastatic colorectal cancer.
@nl
P2093
P2860
P1476
A phase I open-label study of ...... metastatic colorectal cancer.
@en
P2093
A Benjamin Suttle
Cecile de Labareyre
Claire Wixon
Helene Senellart
Jaafar Bennouna
Jean-Pierre Delord
Jeff Botbyl
Marion Deslandres
Rodrigo Ruiz-Soto
P2860
P2888
P304
P356
10.1007/S10637-014-0142-1
P577
2014-09-24T00:00:00Z